Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 26,661 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Advanced Chronic Liver Disease, NASH
Interventions: VCTE with splenic stiffness measurement; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Degenerative Joint Disease of Knee, Osteoarthritis, Traumatic Arthritis, Varus Deformity, Knee Pain Chronic
Interventions: Persona Partial Knee System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Heart Failure
Interventions: Sodium Zirconium Cyclosilicate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: National City, California • Stanford, California • Waterbury, Connecticut + 11 more

Conditions: Crohns Disease
Interventions: N-Acetylglucosamine (GlcNAc); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Operative Pain
Interventions: IV Acetaminophen; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Stress Disorders, Post-traumatic
Interventions: CIC+VA-CRAFT, CIC; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hemoglobins, Diagnostic Tests
Interventions: MyChart message; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Memory Disorders, Multiple Sclerosis
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Efavaleukin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 63
States / cities: Dothan, Alabama • Homewood, Alabama • Mesa, Arizona + 57 more

Conditions: Postmenopausal, Healthy Adult Female Participants
Interventions: LAE102 SC, Placebo SC, LAE102 IV, Placebo IV; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Multiple Sclerosis
Interventions: 4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Postoperative Pain
Interventions: Gabapentin; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 25 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Major Depressive Disorder
Interventions: AZD2066, Placebo, Duloxetine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 13
States / cities: Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Influenza
Interventions: Influenza A/H7N7 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: INCB018424, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more

Conditions: Allergic Conjunctivitis
Interventions: R89674 (generic name not yet established); Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Alzheimer's Dementia
Interventions: Resonator; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastric Ulcer
Interventions: PA32540, EC Aspirin 325; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastroparesis
Interventions: CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more

Conditions: Covid19, Cytokine Release Syndrome
Interventions: dapansutrile capsules, placebo capsules; Drug
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: San Diego, California • Stanford, California • Chicago, Illinois + 6 more

Search by objective public record fields.

Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

A Randomized Controlled Trial for Partial Knee Arthroplasty

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

Oral N-acetylglucosamine in Crohn's Disease

RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

A Randomized Controlled Trial of Coaching Into Care With VA-CRAFT to Promote Veteran Engagement in PTSD Care

Electronic Triggers: Messaging After A1C EHR Alert

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Pain Control With Total Knee Replacement

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy